Floatz logo

Sulfur hexafluoride

Atherosclerosis

Enrico AmmiratiSmall moleculePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Atherosclerosis cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
SIMVASTATIN
Northern California Institute of Research and Education
Phase 4BBB
ADVICOR COMPONENT NIACIN
University of Washington
Phase 4BB
ATORVASTATIN
Erasmus Medical Center
Phase 4BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Asan Medical Center
Phase 4BB

View all 45 →

Same molecule, other indications

Sulfur hexafluoride is also rated in:

renal cell carcinomaActive
BB
Indicative · Phase 4
67 / 100
View asset →
stroke disorderDormant
B
Indicative · Phase 2
62 / 100
View asset →
carotid stenosisDormant
B
Indicative · Phase 3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →